197 related articles for article (PubMed ID: 35906623)
1. Dose escalation based on
Zhu H; Liu Q; Xu H; Mo M; Wang Z; Lu K; Zhou J; Chen J; Zheng X; Ye J; Ge X; Luo H; Liu Q; Deng J; Ai D; Hao S; Zhang J; Tseng IH; Song S; Chen Y; Zhao K
Radiat Oncol; 2022 Jul; 17(1):134. PubMed ID: 35906623
[TBL] [Abstract][Full Text] [Related]
2. Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2).
Ai D; Chen Y; Liu Q; Zhang J; Deng J; Zhu H; Ren W; Zheng X; Li Y; Wei S; Ye J; Zhou J; Lin Q; Luo H; Cao J; Li J; Huang G; Wu K; Fan M; Yang H; Zhu Z; Zhao W; Li L; Fan J; Badakhshi H; Zhao K
BMJ Open; 2018 Oct; 8(10):e020785. PubMed ID: 30344165
[TBL] [Abstract][Full Text] [Related]
3. FDG PET using SUV
Huang YC; Lu HI; Huang SC; Hsu CC; Chiu NT; Wang YM; Chiu YC; Li SH
BMC Med Imaging; 2017 Jan; 17(1):1. PubMed ID: 28056868
[TBL] [Abstract][Full Text] [Related]
4. Diffusion-weighted MRI and
Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
[TBL] [Abstract][Full Text] [Related]
5. A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol.
Gao LR; Wang X; Han W; Deng W; Li C; Wang X; Zhao Y; Ni W; Chang X; Zhou Z; Deng L; Wang W; Liu W; Liang J; Zhang T; Bi N; Wang J; Zhai Y; Feng Q; Lv J; Li L; Xiao Z
BMC Cancer; 2020 Sep; 20(1):901. PubMed ID: 32962674
[TBL] [Abstract][Full Text] [Related]
6. Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial.
Pöttgen C; Gkika E; Stahl M; Abu Jawad J; Gauler T; Kasper S; Trarbach T; Herrmann K; Lehmann N; Jöckel KH; Lax H; Stuschke M
Radiat Oncol; 2021 Mar; 16(1):59. PubMed ID: 33757534
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol.
Chen Y; Zhu Z; Zhao W; Li L; Ye J; Wu C; Tang H; Lin Q; Li J; Xia Y; Li Y; Zhou J; Zhao K
Radiat Oncol; 2018 Feb; 13(1):33. PubMed ID: 29482649
[TBL] [Abstract][Full Text] [Related]
8. To evaluate the treatment response of locally advanced esophageal cancer after preoperative chemoradiotherapy by FDG-PET/CT scan.
Huang JW; Yeh HL; Hsu CP; Lu YY; Chuang CY; Lin JC; Lin JF; Chang CF
J Chin Med Assoc; 2015 Apr; 78(4):229-34. PubMed ID: 25557468
[TBL] [Abstract][Full Text] [Related]
9. Combined pretreatment with
Ji S; Hu Q; Zhu J; Chen J; Chen Q; Liu Z; Shen C; Yang R; Sun H; Wu J; Gu K
Trials; 2018 Aug; 19(1):416. PubMed ID: 30075736
[TBL] [Abstract][Full Text] [Related]
10. High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer.
Calais J; Dubray B; Nkhali L; Thureau S; Lemarignier C; Modzelewski R; Gardin I; Di Fiore F; Michel P; Vera P
Eur J Nucl Med Mol Imaging; 2015 May; 42(6):858-67. PubMed ID: 25680400
[TBL] [Abstract][Full Text] [Related]
11. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
Nestle U; Schimek-Jasch T; Kremp S; Schaefer-Schuler A; Mix M; Küsters A; Tosch M; Hehr T; Eschmann SM; Bultel YP; Hass P; Fleckenstein J; Thieme A; Stockinger M; Dieckmann K; Miederer M; Holl G; Rischke HC; Gkika E; Adebahr S; König J; Grosu AL;
Lancet Oncol; 2020 Apr; 21(4):581-592. PubMed ID: 32171429
[TBL] [Abstract][Full Text] [Related]
12. Role of
Sasaki K; Uchikado Y; Okumura H; Omoto I; Kita Y; Arigami T; Uenosono Y; Owaki T; Maemura K; Natsugoe S
Anticancer Res; 2017 Feb; 37(2):859-864. PubMed ID: 28179343
[TBL] [Abstract][Full Text] [Related]
13. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
[TBL] [Abstract][Full Text] [Related]
14. Extensive clinical target volume in postoperative chemoradiotherapy for esophageal squamous cell carcinoma: a phase II clinical trial (ESO-Shanghai 9).
Ai D; Chen Y; Liu Q; Deng J; Zhang X; Zhang J; Chu L; Shen J; Ma L; Zhang Y; Chen H; Miao L; Zhao K; Xiang J
Radiat Oncol; 2023 Feb; 18(1):26. PubMed ID: 36750858
[TBL] [Abstract][Full Text] [Related]
15. Response Prediction Using
Hu X; Zhou T; Ren J; Duan J; Wu H; Liu X; Mu Z; Liu N; Wei Y; Yuan S
J Nucl Med; 2023 Apr; 64(4):625-631. PubMed ID: 36229183
[TBL] [Abstract][Full Text] [Related]
16. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
[TBL] [Abstract][Full Text] [Related]
17. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T
BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286
[TBL] [Abstract][Full Text] [Related]
18. Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial.
Kong FM; Ten Haken RK; Schipper M; Frey KA; Hayman J; Gross M; Ramnath N; Hassan KA; Matuszak M; Ritter T; Bi N; Wang W; Orringer M; Cease KB; Lawrence TS; Kalemkerian GP
JAMA Oncol; 2017 Oct; 3(10):1358-1365. PubMed ID: 28570742
[TBL] [Abstract][Full Text] [Related]
19. Involved-Field Irradiation in Definitive Chemoradiotherapy for Locoregional Esophageal Squamous Cell Carcinoma: Results From the ESO-Shanghai 1 Trial.
Zhu H; Rivin Del Campo E; Ye J; Simone CB; Zhu Z; Zhao W; Amini A; Zhou J; Wu C; Tang H; Fan M; Li L; Lin Q; Xia Y; Li Y; Li J; Mo M; Jia H; Lu S; Wang J; Nie Y; Chen J; Wu S; Hamaji M; Haque W; Jeong BK; Shridhar R; Zhang Z; Chen Y; Zhao K
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1396-1406. PubMed ID: 33677048
[TBL] [Abstract][Full Text] [Related]
20. Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
Jeong Y; Kim JH; Kim SB; Yoon DH; Park SI; Kim YH; Kim HR; Jung HY; Lee GH; Ryu JS
J Surg Oncol; 2014 Apr; 109(5):472-7. PubMed ID: 24301552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
